2'-chloro-2'-deoxyadenosine profile

2'-Chloro-2'-deoxyadenosine (2'-Cl-dAdo) is a synthetic nucleoside analog that has shown promise as an antiviral agent. It is a potent inhibitor of viral DNA polymerases, including those of herpes simplex virus, varicella-zoster virus, and cytomegalovirus. 2'-Cl-dAdo is also a substrate for adenosine deaminase, which converts it to 2'-chloro-2'-deoxyinosine (2'-Cl-dIno). 2'-Cl-dIno is a potent inhibitor of viral RNA polymerases, including those of influenza virus and respiratory syncytial virus. 2'-Cl-dAdo has been studied as a potential treatment for a variety of viral infections, including herpes simplex virus encephalitis, varicella-zoster virus infection, cytomegalovirus retinitis, influenza, and respiratory syncytial virus infection.'

ID Source	ID
PubMed CID	100327
SCHEMBL ID	600802
MeSH ID	M0111918

Synonym
nsc-289354
2627-62-5
2'-chloro-2'-deoxyadenosine
adenosine, 2'-chloro-2'-deoxy-
unii-3mr7o4xf3u
3mr7o4xf3u ,
2'-deoxy-2'-chloroadenosine
nsc 289354
SCHEMBL600802
J-700374
DTXSID20180898
2'-chlorodeoxyadenosine
(2r,3r,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-chloro-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2r,3r,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-chloro-2-(hydroxymethyl)oxolan-3-ol

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (50.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (12.50%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	2 (25.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.01	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.01	1	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.21	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
propidium Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.	1.99	1	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic.	7.21	1	0	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite
2-chloroadenosine 5-chloroformycin A: structure given in first source	6.92	8	1	purine nucleoside
2'-deoxyadenosine triphosphate 2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd	2.08	1	0	2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.01	1	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
fludarabine [no description available]	2.01	1	0	purine nucleoside
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.01	1	0	ammonium ion derivative
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.01	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor

Condition	Relationship Strength	Studies	Trials
Hand-Schu00FCller-Christian Disease [description not available]	4.35	1	1
Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder.	4.35	1	1
Airflow Obstruction, Chronic [description not available]	2.08	1	0
Anoxemia [description not available]	2.08	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.08	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	2.08	1	0
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	1.98	1	0
Hairy Cell Leukemia [description not available]	1.98	1	0
Acute Hemolytic Transfusion Reaction [description not available]	1.98	1	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	1.98	1	0
Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.	1.98	1	0
Transfusion Reaction Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.	1.98	1	0
Tumour Lysis Syndrome [description not available]	1.98	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.4	2	0
Tumor Lysis Syndrome A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.	1.98	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.4	2	0
Blood Diseases [description not available]	2.9	1	0
Benign Neoplasms [description not available]	2.9	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	2.9	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.9	1	0

2'-chloro-2'-deoxyadenosine

Cross-References

Synonyms (14)

Research

Studies (8)

Market Indicators

Research Demand Index: 19.75

Study Types